Cambridge, United Kingdom, 13th February 2024 / Domainex, a leading drug discovery and integrated medicines research partner based in Cambridge UK, opens a new Biology Centre of Excellence to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.

The grand opening on the 7th February was officiated by Mrs Julie Spence OBE CStJ QPM, HM Lord-Lieutenant of Cambridgeshire, who also presented the King’s Award for Enterprise: International Trade 2023 to Domainex’s CEO, Dr Tom Mander. Approximately, 50 guests, including senior executives from leading biotechnology companies and local dignitaries, attended the opening event and were offered guided tours of the facility.

The new three-storey, state-of-the-art facility provides over 24,000 sq ft for Domainex’s expanding biology/bioanalytical departments. The building, based at the Unity Campus at Pampisford, is located in a fast-growing Cambridge hub for life-science innovation with excellent transport links. It provides a more than three-fold increase on the previous footprint to allow continued, rapid expansion of people and equipment to support Domainex’s ambition to provide innovative and customised drug discovery services to a growing client-base globally.

The facility will be able to house more than 100 scientists including biochemists, biophysicists, cell biologists, protein scientists, bioanalysts and structural biologists. With the existing Chemistry Centre of Excellence at Chesterford Research Park, the combined footprint of Domainex’s research facilities in the Cambridge life science hub now exceeds 44,000 sq ft.

The King’s Award for Enterprise: International Trade 2023, recognises the company’s outstanding growth in international trade over three years, which amounted to a more than one hundred per cent increase in international revenues during the period. This growth was achieved entirely organically and is a testament to the company’s excellent reputation and commitment to delivering high-quality drug discovery services for its life science clients.

Domainex received several other awards during 2023, including the Cambridge Independent SME awards for High Growth Business of the Year (Gold) and Business of the Year – more than 50 employees (Silver) and Business Weekly’s Life Sciences Scale-up Award.

Mrs Julie Spence OBE CStJ QPM, HM Lord-Lieutenant, said, “It was my pleasure to open Domainex’s new Biology Centre of Excellence and to present the King’s Award for Enterprise to Domainex’s CEO, Dr Tom Mander. The King’s Awards are the most prestigious awards available to UK businesses,  are highly competitive and only awarded to the best. I would like to congratulate Domainex  on this fantastic achievement and on the opening of their new facility which will allow them  to expand the high-quality, innovative drug discovery services for which they are  globally renowned.”

Dr Tom Mander, CEO of Domainex, commented, “We are deeply honoured to receive the prestigious King’s Award from HM Lord-Lieutenant of Cambridgeshire, and are privileged that the Lord-Lieutenant has also opened our new building. Our exciting new facility will enable us to continue to expand the range of our services and will help bring much needed treatments to patients faster and more effectively.”

Dr Trevor Askwith, Head of Biology, added, “The whole team is delighted with the new facility and space to expand our biology and bioanalytical capabilities. We are continually investing in cutting-edge technologies and developing new services. We launched a new cryo-EM service last year and recently expanded our suite of biophysical instrumentation by adding spectral shift technology, a third, multi-channel Grating Coupled Interferometry WAVEdelta system and a PEAQ-ITC instrument. The additional space will allow for further expansion and innovation.”


For further information, please contact:

Dr Tom Mander, CEO

Sciad Communications
Juliette Craggs / Maria Taylor
T: +44 (0)20 3405 7892

Notes for Editors

Based in Cambridge, UK and employing over 100 scientists, 95% of whom are educated to at least Master’s degree level, Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.

Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Domainex leverages its considerable knowledge of drug discovery to provide intellectual input, creativity and innovation to maximise the chance of successful identification of drug candidates to treat debilitating diseases. Domainex works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.

Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs.

Full information about Domainex and its award-winning services can be found at



Domainex is a multi-award winning, integrated drug discovery CRO and has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. They work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world.

Visit website

Got an innovation you need bringing to life?

We’d love to hear from you! Head to our contact page to start a conversation.

Photo of Esther Gibson